Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8438)
All Articles published online
|
May 26, 2010 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Biological Chemistry
ISSN
1949-8454
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010; 1(5): 55-61 [PMID: 21540990 DOI: 10.4331/wjbc.v1.i5.55] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8454/full/v1/i5/55.htm |
| Number | Citing Articles |
| 1 |
Jesse E. Hanson, Lunbin Deng, David H. Hackos, Shih-Ching Lo, Benjamin E. Lauffer, Pascal Steiner, Qiang Zhou. Histone Deacetylase 2 Cell Autonomously Suppresses Excitatory and Enhances Inhibitory Synaptic Function in CA1 Pyramidal Neurons. The Journal of Neuroscience 2013; 33(14): 5924 doi: 10.1523/JNEUROSCI.3162-12.2013
|
| 2 |
SUSANNE GAHR, CHRISTIAN MAYR, TOBIAS KIESSLICH, ROMANA ILLIG, DANIEL NEUREITER, BEATE ALINGER, MARION GANSLMAYER, TILL WISSNIOWSKI, PIETRO DI FAZIO, ROBERTA MONTALBANO, JOACHIM H. FICKER, MATTHIAS OCKER, KARL QUINT. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International Journal of Oncology 2015; 47(3): 963 doi: 10.3892/ijo.2015.3087
|
| 3 |
Rajesh Singh, James W. Lillard, Shailesh Singh. Epigenetic Advancements in Cancer. 2016; : 27 doi: 10.1007/978-3-319-24951-3_2
|
| 4 |
Androniki Kretsovali, Christiana Hadjimichael, Nikolaos Charmpilas. Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming. Stem Cells International 2012; 2012: 1 doi: 10.1155/2012/184154
|
| 5 |
Michael J. Morris, Lisa M. Monteggia. Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. International Journal of Developmental Neuroscience 2013; 31(6): 370 doi: 10.1016/j.ijdevneu.2013.02.005
|
| 6 |
H. A. Gefroh-Grimes, B. E. Gidal. Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. Acta Neurologica Scandinavica 2016; 133(1): 4 doi: 10.1111/ane.12437
|
| 7 |
Maulik Patel, Sandip Pravin Patel, Razelle Kurzrock. Early Phase Cancer Immunotherapy. Current Cancer Research 2018; : 243 doi: 10.1007/978-3-319-63757-0_9
|
| 8 |
MARIA DE LOURDES PESSOLE BIONDO-SIMÕES, MOACIR OLIVEIRA DALL’ANTONIA, MATHEUS PRINCE GOEHR, RACHEL BIONDO-SIMÕES, SÉRGIO OSSAMU IOSHII, ROGÉRIO RIBEIRO ROBES. Valproic acid and bladder healing: an experimental study in rats. Revista do Colégio Brasileiro de Cirurgiões 2022; 49 doi: 10.1590/0100-6991e-20223399-en
|
| 9 |
Misun Kim, Yoojung Kwon, Hyun Suk Jung, Youngmi Kim, Dooil Jeoung. FcεRI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions. International Journal of Molecular Sciences 2019; 20(19): 4964 doi: 10.3390/ijms20194964
|
| 10 |
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Vasiliki E. Georgakopoulou, Panagiotis Sarantis, Efstathios A. Antoniou, Michalis V. Karamouzis, Afroditi Nonni, Dimitrios Schizas, Evangelos Diamantis, Evangelos Koustas, Paraskevi Farmaki, Athanasios Syllaios, Alexandros Patsouras, Konstantinos Kontzoglou, Nikolaos Trakas, Dimitrios Dimitroulis. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities. Journal of Personalized Medicine 2021; 11(3): 223 doi: 10.3390/jpm11030223
|
| 11 |
Sebastian Stintzing, Ralf Kemmerling, Tobias Kiesslich, Beate Alinger, Matthias Ocker, Daniel Neureiter, Patrick Matthias. Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?. BioMed Research International 2011; 2011(1) doi: 10.1155/2011/214143
|
| 12 |
Pietro Di Fazio, Roberta Montalbano, Daniel Neureiter, Beate Alinger, Ansgar Schmidt, Anna Lena Merkel, Karl Quint, Matthias Ocker. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Experimental Cell Research 2012; 318(15): 1832 doi: 10.1016/j.yexcr.2012.04.018
|
| 13 |
H M Tang, K T Kuay, P F Koh, M Asad, T Z Tan, V Y Chung, S C Lee, J P Thiery, RY-J Huang. An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discovery 2016; 2(1) doi: 10.1038/cddiscovery.2016.41
|
| 14 |
P. Ann Boriack‐Sjodin. Structural Biology in Drug Discovery. 2020; : 423 doi: 10.1002/9781118681121.ch18
|
| 15 |
M. Ocker, M. Höpfner. Apoptosis-Modulating Drugs for Improved Cancer Therapy. European Surgical Research 2012; 48(3): 111 doi: 10.1159/000336875
|
| 16 |
Florian Thaler, Loris Moretti, Raffaella Amici, Agnese Abate, Andrea Colombo, Giacomo Carenzi, Maria Carmela Fulco, Roberto Boggio, Giulio Dondio, Stefania Gagliardi, Saverio Minucci, Luca Sartori, Mario Varasi, Ciro Mercurio. Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. European Journal of Medicinal Chemistry 2016; 108: 53 doi: 10.1016/j.ejmech.2015.11.010
|
| 17 |
Steven Behnisch-Cornwell, Christoph W. Grathwol, Lukas Schulig, Anika Voigt, Daniel Baecker, Andreas Link, Patrick J. Bednarski. Correlation Analysis of Protein Expression of 10 HDAC/Sirtuin Isoenzymes with Sensitivities of 23 Anticancer Drugs in 17 Cancer Cell Lines and Potentiation of Drug Activity by Co-Treatment with HDAC Inhibitors. Cancers 2021; 14(1): 187 doi: 10.3390/cancers14010187
|
| 18 |
Daniel Neureiter, Sebastian Stintzing, Tobias Kiesslich, Matthias Ocker. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World Journal of Gastroenterology 2019; 25(25): 3136-3150 doi: 10.3748/wjg.v25.i25.3136
|
| 19 |
Somprasong Khaopha, Sanun Jogloy, Aran Patanothai, Thanaset Senawong. Histone Deacetylase Inhibitory Activity of Peanut Testa Extracts against Human Cancer Cell Lines. Journal of Food Biochemistry 2015; 39(3): 263 doi: 10.1111/jfbc.12128
|
| 20 |
Mohammad-Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, Yosra Vaez-Gharamaleki, Mahsa Akbarzadeh. Histone deacetylase inhibitors for leukemia treatment: current status and future directions. European Journal of Medical Research 2024; 29(1) doi: 10.1186/s40001-024-02108-8
|
| 21 |
Ping Gong, Kun Li, Ying Li, Dan Liu, Linxiang Zhao, Yongkui Jing. HDAC and Ku70 axis- an effective target for apoptosis induction by a new 2-cyano-3-oxo-1,9-dien glycyrrhetinic acid analogue. Cell Death & Disease 2018; 9(6) doi: 10.1038/s41419-018-0602-1
|
| 22 |
Elizabeth E. Hull, McKale R. Montgomery, Kathryn J. Leyva. HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. BioMed Research International 2016; 2016: 1 doi: 10.1155/2016/8797206
|
| 23 |
Marcella La Noce, Luigi Mele, Luigi Laino, Giovanni Iolascon, Gorizio Pieretti, Gianpaolo Papaccio, Vincenzo Desiderio, Virginia Tirino, Francesca Paino. Cytoplasmic Interactions between the Glucocorticoid Receptor and HDAC2 Regulate Osteocalcin Expression in VPA-Treated MSCs. Cells 2019; 8(3): 217 doi: 10.3390/cells8030217
|
| 24 |
MARIA DE LOURDES PESSOLE BIONDO-SIMÕES, MOACIR OLIVEIRA DALL’ANTONIA, MATHEUS PRINCE GOEHR, RACHEL BIONDO-SIMÕES, SÉRGIO OSSAMU IOSHII, ROGÉRIO RIBEIRO ROBES. Ácido valpróico e cicatrização em bexiga: estudo experimental em ratos. Revista do Colégio Brasileiro de Cirurgiões 2022; 49 doi: 10.1590/0100-6991e-20223399
|
| 25 |
Steffen Zopf, Matthias Ocker, Daniel Neureiter, Beate Alinger, Susanne Gahr, Markus F Neurath, Pietro Di Fazio. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-386
|
| 26 |
Ahmed Sawas, Owen A O’Connor. Belinostat for the treatment of T-cell lymphoma. Expert Opinion on Orphan Drugs 2015; 3(2): 219 doi: 10.1517/21678707.2015.997209
|
| 27 |
Chiara Facciotto, Julia Casado, Laura Turunen, Suvi-Katri Leivonen, Manuela Tumiati, Ville Rantanen, Liisa Kauppi, Rainer Lehtonen, Sirpa Leppä, Krister Wennerberg, Sampsa Hautaniemi. Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer. Clinical Epigenetics 2019; 11(1) doi: 10.1186/s13148-019-0781-3
|
| 28 |
Anita M.A.P. Govers, Caroline R.M. Wiggers, Ruben van Boxtel, Michal Mokry, Edward E.S. Nieuwenhuis, Menno P. Creyghton, Marije Bartels, Paul J. Coffer. Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development. HemaSphere 2019; 3(4) doi: 10.1097/HS9.0000000000000270
|
| 29 |
J. Fraczek, J. Bolleyn, T. Vanhaecke, V. Rogiers, M. Vinken. Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies. Archives of Toxicology 2013; 87(4): 577 doi: 10.1007/s00204-012-0983-3
|
| 30 |
Alexander Henrici, Roberta Montalbano, Daniel Neureiter, Michael Krause, Thorsten Stiewe, Emily Prentice Slater, Karl Quint, Matthias Ocker, Pietro Di Fazio. The pan‐deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Molecular Carcinogenesis 2015; 54(8): 585 doi: 10.1002/mc.22122
|
| 31 |
PIETRO DI FAZIO, ROBERTA MONTALBANO, KARL QUINT, BEATE ALINGER, RALF KEMMERLING, TOBIAS KIESSLICH, MATTHIAS OCKER, DANIEL NEUREITER. The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models. Oncology Letters 2013; 5(1): 127 doi: 10.3892/ol.2012.951
|
| 32 |
Yong Jung Kang, Young Hoon Kwon, Jung Yoon Jang, Jun Ho Lee, Sanggwon Lee, Yujin Park, Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim. MHY2251, a New SIRT1 Inhibitor, Induces Apoptosis via JNK/p53 Pathway in HCT116 Human Colorectal Cancer Cells. Biomolecules & Therapeutics 2023; 31(1): 73 doi: 10.4062/biomolther.2022.044
|
| 33 |
Ayako Kanamoto, Itasu Ninomiya, Shinichi Harada, Tomoya Tsukada, Koichi Okamoto, Shinichi Nakanuma, Seisho Sakai, Isamu Makino, Jun Kinoshita, Hironori Hayashi, Katsunobu Oyama, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Sachio Fushida, Tetsuo Ohta. Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma. International Journal of Oncology 2016; 49(5): 1859 doi: 10.3892/ijo.2016.3712
|
| 34 |
Liam Lawlor, Xuebin B. Yang. Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering. International Journal of Oral Science 2019; 11(2) doi: 10.1038/s41368-019-0053-2
|
| 35 |
Ramiya Islam, Rashmi Singh. Curcumin and PCI-34051 combined treatment ameliorates inflammation and fibrosis by affecting MAP kinase pathway. Inflammopharmacology 2023; 31(6): 3063 doi: 10.1007/s10787-023-01371-1
|
| 36 |
Michael R. Cassidy, Alan C. Sherburne, Holly K. Sheldon, Melanie L. Gainsbury, Stanley Heydrick, Arthur F. Stucchi. Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Surgery 2014; 155(2): 234 doi: 10.1016/j.surg.2013.08.018
|
| 37 |
Katharina Mahal, Philip Kahlen, Bernhard Biersack, Rainer Schobert. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide – A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. Experimental Cell Research 2015; 336(2): 263 doi: 10.1016/j.yexcr.2015.06.008
|
| 38 |
Simon Scheuerer, Lucia Motlova, Linda Schäker-Hübner, Andreas Sellmer, Felix Feller, Fabian J. Ertl, Pierre Koch, Finn K. Hansen, Cyril Barinka, Siavosh Mahboobi. Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability. European Journal of Medicinal Chemistry 2024; 276: 116676 doi: 10.1016/j.ejmech.2024.116676
|
| 39 |
Manuela Terranova-Barberio, Scott Thomas, Pamela N Munster. Epigenetic Modifiers in Immunotherapy: a Focus on Checkpoint Inhibitors. Immunotherapy 2016; 8(6): 705 doi: 10.2217/imt-2016-0014
|
| 40 |
TOBIAS KIESSLICH, MARTIN PICHLER, DANIEL NEUREITER. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Molecular and Clinical Oncology 2013; 1(1): 3 doi: 10.3892/mco.2012.28
|
| 41 |
Roberta Montalbano, Petra Waldegger, Karl Quint, Samir Jabari, Daniel Neureiter, Romana Illig, Matthias Ocker, Pietro Di Fazio. Endoplasmic Reticulum Stress Plays a Pivotal Role in Cell Death Mediated by the Pan-Deacetylase Inhibitor Panobinostat in Human Hepatocellular Cancer Cells. Translational Oncology 2013; 6(2): 143 doi: 10.1593/tlo.12271
|
| 42 |
Michiel Alexander De Raaf, Aysar Al Hussaini, Jose G. Gomez‐Arroyo, Donatas Kraskaukas, Daniela Farkas, Chris Happé, Norbert F. Voelkel, Harm Jan Bogaard. Histone Deacetylase Inhibition with Trichostatin a does not Reverse Severe Angioproliferative Pulmonary Hypertension in Rats (2013 Grover Conference Series). Pulmonary Circulation 2014; 4(2): 1 doi: 10.1086/675986
|
| 43 |
Omana P. Mathew, Kasturi Ranganna, Joseph Mathew, Meiling Zhu, Zivar Yousefipour, Chelliah Selvam, Shirlette G. Milton. Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are Mediated through Disparate Actions on Dual Targets, Histone Deacetylase (HDAC) Activity and PI3K/Akt Signaling Network. International Journal of Molecular Sciences 2019; 20(12): 2902 doi: 10.3390/ijms20122902
|
| 44 |
Yekaterina Kori, Simone Sidoli, Zuo-Fei Yuan, Peder J. Lund, Xiaolu Zhao, Benjamin A. Garcia. Proteome-wide acetylation dynamics in human cells. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-09918-3
|
| 45 |
Matthias Ocker, Samar Al Bitar, Ana Carolina Monteiro, Hala Gali-Muhtasib, Regine Schneider-Stock. Epigenetic Regulation of p21cip1/waf1 in Human Cancer. Cancers 2019; 11(9): 1343 doi: 10.3390/cancers11091343
|
| 46 |
Florian Thaler, Mario Varasi, Agnese Abate, Giacomo Carenzi, Andrea Colombo, Chiara Bigogno, Roberto Boggio, Roberto Dal Zuffo, Daniela Rapetti, Anna Resconi, Nickolas Regalia, Stefania Vultaggio, Giulio Dondio, Stefania Gagliardi, Saverio Minucci, Ciro Mercurio. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4′-piperidine] based histone deacetylase inhibitors. European Journal of Medicinal Chemistry 2013; 64: 273 doi: 10.1016/j.ejmech.2013.03.061
|
| 47 |
Annalisa Adamo, Cristina Frusteri, Maria Teresa Pallotta, Tracey Pirali, Silvia Sartoris, Stefano Ugel. Moonlighting Proteins Are Important Players in Cancer Immunology. Frontiers in Immunology 2021; 11 doi: 10.3389/fimmu.2020.613069
|
| 48 |
Carmina Micelli, Giulio Rastelli. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discovery Today 2015; 20(6): 718 doi: 10.1016/j.drudis.2015.01.007
|
| 49 |
Marc‐Andrea Baertsch, Jens Hillengass, Joanna Blocka, Stefan Schönland, Ute Hegenbart, Hartmut Goldschmidt, Marc S. Raab. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. Hematological Oncology 2018; 36(1): 210 doi: 10.1002/hon.2462
|
| 50 |
Karl Quint, Abbas Agaimy, Pietro Di Fazio, Roberta Montalbano, Claudia Steindorf, Rudolf Jung, Claus Hellerbrand, Arndt Hartmann, Helmut Sitter, Daniel Neureiter, Matthias Ocker. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Archiv 2011; 459(2): 129 doi: 10.1007/s00428-011-1103-0
|